Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 13, 2026, 2:16 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 97–120 of 189 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Cohort 1 - Group 1/2 Placebo Clear all
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Study to Determine the Safety, Tolerability and Pharmacokinetics of UV-4B Solution Administered Orally in Healthy Subjects

NCT02061358
View directory record Official record
Conditions
Viral Infection
Interventions
UV-4B 3 mg, UV-4B 10 mg, UV-4B 30 mg, UV-4B 90 mg, UV-4B 180 mg, UV-4B 360 mg, UV-4B 720 mg, UV-4B 1000 mg, Placebo
Drug
Lead sponsor
Emergent BioSolutions
Industry
Eligibility
18 Years to 45 Years
Enrollment
64 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2015
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Mar 18, 2024 · Synced Oct 13, 2026, 2:16 AM EDT
Completed No phase listed Observational Results available

Assessing Tele-Health Outcomes in Multiyear Extensions of PD Trials

NCT03538262
View directory record Official record
Conditions
Parkinson Disease
Interventions
Not listed
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
Not listed
Enrollment
226 participants
Timeline
2018 – 2022
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated Jun 12, 2023 · Synced Oct 13, 2026, 2:16 AM EDT
Completed Phase 1Phase 2 Interventional Results available

A Study of Olaratumab (LY3012207) in Participants With Advanced Soft Tissue Sarcoma

NCT02659020
View directory record Official record
Conditions
Soft Tissue Sarcoma
Interventions
Olaratumab, Gemcitabine, Docetaxel, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
16 Years and older
Enrollment
310 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
21
States / cities
Santa Monica, California • Aurora, Colorado • Jacksonville, Florida + 17 more
Source: ClinicalTrials.gov public record
Updated May 9, 2022 · Synced Oct 13, 2026, 2:16 AM EDT
Recruiting Phase 2 Interventional

A Study to Investigate the Safety and Efficacy of MEDI0618 Compared to Placebo in Adult Participants With Episodic Migraine

NCT06602479
View directory record Official record
Conditions
Migraine
Interventions
MEDI0618, Placebo
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years to 70 Years
Enrollment
488 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
16
States / cities
Birmingham, Alabama • Huntsville, Alabama • La Jolla, California + 13 more
Source: ClinicalTrials.gov public record
Updated May 19, 2026 · Synced Oct 13, 2026, 2:16 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Phase 1, TAK-915-1001, Single-Rising Dose, Multiple-Rising Dose, Drug-Drug Interaction, Relative Bioavailability, Food Effect, and Effect on Elderly Participants Study

NCT02461160
View directory record Official record
Conditions
Healthy Volunteers
Interventions
TAK-915 suspension, Midazolam, Placebo, TAK-915 tablet
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years to 75 Years
Enrollment
88 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2016
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Feb 15, 2019 · Synced Oct 13, 2026, 2:16 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Phase 1, Single-Ascending-Dose, Safety, Tolerability, Pharmacokinetic(PK), and Pharmacodynamic(PD) Study of BIIB068 in Healthy Participants

NCT02829541
View directory record Official record
Conditions
Systemic Lupos Erythematosus, SLE
Interventions
BIIB068, Placebo
Drug
Lead sponsor
Biogen
Industry
Eligibility
18 Years to 55 Years
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016
U.S. locations
1
States / cities
Evansville, Indiana
Source: ClinicalTrials.gov public record
Updated Mar 15, 2017 · Synced Oct 13, 2026, 2:16 AM EDT
Terminated Phase 2 Interventional Results available

A Study to Assess the Hemodynamic Effects, Safety, Tolerability, and Pharmacokinetics of Intravenous APD418 in Adult Participants With Heart Failure With Reduced Ejection Fraction

NCT05139615
View directory record Official record
Conditions
Acute Heart Failure With Reduced Ejection Fraction
Interventions
APD418, Placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 85 Years
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
5
States / cities
Tampa, Florida • Peoria, Illinois • Houston, Texas + 2 more
Source: ClinicalTrials.gov public record
Updated Nov 9, 2023 · Synced Oct 13, 2026, 2:16 AM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers Results available

Assess the Safety and Immunogenicity of One or Two Doses of Sing2016 M2SR H3N2 Influenza Vaccine

NCT04960397
View directory record Official record
Conditions
H3N2 Influenza
Interventions
Placebo, Sing2016 M2SR H3N2
Other · Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
6 Months to 17 Years
Enrollment
140 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2024
U.S. locations
4
States / cities
Iowa City, Iowa • Baltimore, Maryland • Durham, North Carolina + 1 more
Source: ClinicalTrials.gov public record
Updated Aug 3, 2025 · Synced Oct 13, 2026, 2:16 AM EDT
Recruiting Phase 2 Interventional

The CARDIOPROTECT Trial

NCT07654426
View directory record Official record
Conditions
Diffuse Large B-cell Lymphoma (DLBCL), Cardiotoxicity, Lymphoma
Interventions
Dexrazoxane, Dexrazoxane placebo, Doxorubicin, Liposomal Doxorubicin, Cyclophosphamide, Vincristine, Prednisone, Rituximab, Polatuzumab Vedotin
Drug
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2035
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 27, 2026 · Synced Oct 13, 2026, 2:16 AM EDT
Completed Phase 1 Interventional

Multiple Dose, Dose Escalation Study of Varenicline Controlled Release Formulation in Adult Smokers

NCT00527150
View directory record Official record
Conditions
Smoking Cessation
Interventions
Varenicline Tartrate
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 55 Years
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
2
States / cities
East Grand Forks, Minnesota • Fargo, North Dakota
Source: ClinicalTrials.gov public record
Updated Jan 11, 2010 · Synced Oct 13, 2026, 2:16 AM EDT
Withdrawn Not applicable Interventional

Crossover Blinded Trial of Cell Therapy Versus Placebo in COPD

NCT03228121
View directory record Official record
Conditions
COPD, Emphysema or COPD, Chronic Bronchitis
Interventions
Treatment Then Placebo, Placebo Then Treatment
Procedure
Lead sponsor
Lung Institute
Industry
Eligibility
16 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Sep 13, 2018 · Synced Oct 13, 2026, 2:16 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Safety Study to Evaluate Pazopanib Eye Drops in Healthy Volunteers

NCT01072214
View directory record Official record
Conditions
Macular Degeneration
Interventions
pazopanib, Placebo
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
20 Years to 64 Years
Enrollment
37 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010
U.S. locations
1
States / cities
Glendale, California
Source: ClinicalTrials.gov public record
Updated Nov 14, 2017 · Synced Oct 13, 2026, 2:16 AM EDT
Completed Phase 2 Interventional Results available

A Study to Investigate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Efficacy of Risdiplam (RO7034067) in Type 2 and 3 Spinal Muscular Atrophy (SMA) Participants

NCT02908685
View directory record Official record
Conditions
Muscular Atrophy, Spinal
Interventions
Placebo, Risdiplam
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
2 Years to 25 Years
Enrollment
231 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2023
U.S. locations
2
States / cities
Palo Alto, California • New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 24, 2024 · Synced Oct 13, 2026, 2:16 AM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers

Study of a Respiratory Syncytial Virus/Human Metapneumovirus Vaccine Candidate

NCT06134648
View directory record Official record
Conditions
Respiratory Syncytial Virus Infection, Healthy Volunteers, Human Metapneumovirus
Interventions
RSV/hMPV vaccine candidate Dose L, RSV/hMPV vaccine candidate Dose A, RSV/hMPV vaccine candidate Dose B, Placebo
Biological
Lead sponsor
Sanofi Pasteur, a Sanofi Company
Industry
Eligibility
60 Years and older
Enrollment
646 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2026
U.S. locations
10
States / cities
Los Alamitos, California • Los Angeles, California • Rolling Hills Estates, California + 7 more
Source: ClinicalTrials.gov public record
Updated Mar 12, 2026 · Synced Oct 13, 2026, 2:16 AM EDT
Active, not recruiting Phase 2 Interventional

Study of Tenofovir Alafenamide (TAF) in Children and Teen Participants With Chronic Hepatitis B Virus Infection

NCT02932150
View directory record Official record
Conditions
Chronic Hepatitis B
Interventions
TAF, Placebo
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
2 Years to 17 Years
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2029
U.S. locations
15
States / cities
Los Angeles, California • San Diego, California • San Francisco, California + 12 more
Source: ClinicalTrials.gov public record
Updated Jun 18, 2026 · Synced Oct 13, 2026, 2:16 AM EDT
Not listed Phase 1 Interventional

A Phase 1b Study of LAPS-Exendin in Subjects of Type 2 Diabetes Mellitus

NCT02059564
View directory record Official record
Conditions
Diabetes Mellitus
Interventions
HM11260C, Placebo, Victoza
Drug
Lead sponsor
Hanmi Pharmaceutical Company Limited
Industry
Eligibility
18 Years to 70 Years
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
California City, California
Source: ClinicalTrials.gov public record
Updated Feb 11, 2014 · Synced Oct 13, 2026, 2:16 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

A Study of Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of KAN-101 in Celiac Disease (ACeD-it)

NCT05574010
View directory record Official record
Conditions
Celiac Disease
Interventions
Cohort 1 in Part A, Cohort 2 in Part A, Placebo: Group 1 in Part B and Part C, Group 2 in Part B and Part C, Group 3 in Part B and Part C, Group 4 in Part B and Part C
Drug · Other
Lead sponsor
Kanyos Bio, Inc., a wholly-owned subsidiary of Anokion SA
Industry
Eligibility
18 Years to 70 Years
Enrollment
128 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
23
States / cities
Birmingham, Alabama • Anaheim, California • St. Petersburg, Florida + 20 more
Source: ClinicalTrials.gov public record
Updated Mar 10, 2026 · Synced Oct 13, 2026, 2:16 AM EDT
Completed Phase 2 Interventional Results available

A Study Exploring the Safety, Tolerability and Efficacy of a 4 Week Course of INCB018424 in Subjects With Active Rheumatoid Arthritis

NCT00550043
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
INCB018424, Placebo
Drug
Lead sponsor
Incyte Corporation
Industry
Eligibility
18 Years to 70 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
12
States / cities
Huntsville, Alabama • Upland, California • Gainesville, Florida + 9 more
Source: ClinicalTrials.gov public record
Updated Mar 23, 2015 · Synced Oct 13, 2026, 2:16 AM EDT
Completed Phase 2 Interventional Results available

Cisplatin + Etoposide +/- Concurrent ZD6474 in Previously Untreated Extensive Stage Small Cell Lung Cancer

NCT00613626
View directory record Official record
Conditions
Small Cell Lung Cancer
Interventions
Cisplatin, Etoposide, Placebo, ZD6474
Drug
Lead sponsor
Hoosier Cancer Research Network
Other
Eligibility
18 Years and older
Enrollment
74 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2015
U.S. locations
19
States / cities
Newark, Delaware • Chicago, Illinois • Galesburg, Illinois + 13 more
Source: ClinicalTrials.gov public record
Updated Feb 11, 2020 · Synced Oct 13, 2026, 2:16 AM EDT
Completed Phase 2 Interventional

Study of the Safety and Neuroprotective Capacity of Scp776 in Acute Ischemic Stroke

NCT05585606
View directory record Official record
Conditions
Acute Ischemic Stroke (AIS)
Interventions
Placebo, scp776 (1.9 mg/kg), scp776 (3.8 mg/kg), scp776 (4.8 mg/kg), scp776 (all dose levels)
Drug
Lead sponsor
Silver Creek Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
22
States / cities
Scottsdale, Arizona • Tucson, Arizona • Hartford, Connecticut + 18 more
Source: ClinicalTrials.gov public record
Updated Feb 24, 2026 · Synced Oct 13, 2026, 2:16 AM EDT
Active, not recruiting Phase 2 Interventional Results available

Study Assessing the Efficacy, Safety and PK of Alpelisib (BYL719) in Pediatric and Adult Patients With PIK3CA-related Overgrowth Spectrum

NCT04589650
View directory record Official record
Conditions
PIK3CA-related Overgrowth Spectrum (PROS)
Interventions
Alpelisib, Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
0 Days to 100 Years
Enrollment
236 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2031
U.S. locations
11
States / cities
San Francisco, California • Aurora, Colorado • St Louis, Missouri + 7 more
Source: ClinicalTrials.gov public record
Updated Oct 7, 2026 · Synced Oct 13, 2026, 2:16 AM EDT
Completed No phase listed Observational Accepts healthy volunteers Results available

A Laboratory Evaluation of the Humoral Immune Response in Adults and Children to the H1 Hemagglutinin (HA) Stalk Domain and Other Influenza A Virus Protein Epitopes, After Administration of GlaxoSmithKline (GSK) Biologicals' Pandemic Influenza Vaccines

NCT02415842
View directory record Official record
Conditions
Immunologic Tests
Interventions
Serum samples
Other
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
6 Months to 64 Years
Enrollment
414 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2018
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 23, 2019 · Synced Oct 13, 2026, 2:16 AM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

A Study to Evaluate the Outcomes of Cannabinoid (CBD) Roll-on Topical Stick in Primary Total Knee Arthroplasty

NCT04585230
View directory record Official record
Conditions
Pain, Joint, Pain, Postoperative, Total Knee Arthroplasty
Interventions
CBD, Mineral Oil, Placebo
Drug
Lead sponsor
Rothman Institute Orthopaedics
Other
Eligibility
18 Years to 80 Years
Enrollment
92 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 19, 2020 · Synced Oct 13, 2026, 2:16 AM EDT
Completed Phase 2 Interventional Results available

Total Knee Arthroplasty Infiltration Study for Postoperative Analgesia

NCT03015532
View directory record Official record
Conditions
Postoperative Pain
Interventions
HTX-011, Saline Placebo, Bupivicaine HCl, Ropivacaine
Drug
Lead sponsor
Heron Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
285 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
24
States / cities
Mobile, Alabama • Sheffield, Alabama • Phoenix, Arizona + 13 more
Source: ClinicalTrials.gov public record
Updated Mar 2, 2026 · Synced Oct 13, 2026, 2:16 AM EDT